Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms (ATLAS)

3 november 2026 bijgewerkt door: Biogen

Een gerandomiseerde, placebogecontroleerde fase 3-studie met een longitudinale natuurlijke historie-inloop en open-label extensie om BIIB067 te evalueren, gestart bij klinisch presymptomatische volwassenen met een bevestigde superoxidedismutase 1-mutatie

In this study, researchers will learn more about the effects of a drug called tofersen, also known as BIIB067 and QALSODY®, in adults with amyotrophic lateral sclerosis (ALS) who have a superoxide dismutase 1 (SOD1) gene mutation.

One of the causes of ALS is a change (or mutation) in the SOD1 gene, which causes abnormal SOD1 protein to be made. This abnormal protein can cause the motor neurons in people with ALS to break down and die. When neurons are damaged, they release a protein called neurofilament light chain, also known as NfL. Previous studies have shown that NfL levels are higher in people with SOD1-ALS, even before any ALS symptoms appear.

In this study, researchers will look at the effect of tofersen treatment in the earlier stages of the disease, even before ALS symptoms appear. Researchers believe that giving tofersen to patients as early as possible may slow the onset of ALS symptoms and the progression of the disease.

This study will have 4 parts. In Part A, participants will have their health monitored and NfL levels tested on a monthly basis, but they will not receive any study drug. Tofersen or placebo will be given to participants in Parts B, while all participants will receive tofersen in Parts C and D.

The main question that researchers want to answer is:

• How long does it take for ALS symptoms to appear?

Researchers will also learn more about:

  • How many participants develop ALS symptoms within 24 months of the start of Part B
  • Changes in participants' ability to perform their daily activities
  • Changes in participants' ability to breathe
  • How many participants die or need long-term breathing support
  • Changes in NfL levels in the blood
  • Changes in SOD1 protein levels in the fluid around the brain and spinal cord
  • How many participants have adverse events or serious adverse events. Adverse events are health problems that may or may not be caused by the study drug.

The study will be done as follows:

  • Participants will first be screened to check if they can join the study. The screening period will be up to 6 weeks. Participants will join the study only after reading and signing an informed consent form, also known as an ICF.
  • In Part A, participants with presymptomatic ALS will not get any study drugs. Researchers will check the levels of NfL in their blood. Participants will be closely checked for any signs or symptoms of ALS.
  • Once a participant's NfL levels rise to a certain amount, they will move onto Part B.
  • In Part B, participants will be randomly assigned to get either tofersen or a placebo. Neither participants nor researchers will know who gets tofersen or the placebo during Part B. A placebo looks like the study drug but contains no medicine.
  • Participants will get the first 3 doses of tofersen once every 14 days. Afterwards, they will continue getting maintenance doses every 28 days.
  • All doses will be given through an intrathecal (IT) injection done through a lumbar puncture procedure. This involves injecting the drug into the fluid surrounding the spinal cord in the lower back.
  • Participants who develop ALS symptoms during Part B will move to Part C to receive tofersen.
  • Participants who develop ALS symptoms during Part A will move to Part D to receive tofersen.
  • In both Parts C and D, participants will know they are receiving tofersen.
  • Throughout the study, doctors will measure any changes to the participants' function and quality of life using different questionnaires. Doctors will also take blood and urine samples. They will also check the participants' overall health and ask how they are feeling.
  • Participants will have a follow-up visit 28 days after their last dose of study drug.
  • Participants will be in this study for up to about 6.5 years.

Studie Overzicht

Gedetailleerde beschrijving

The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability of tofersen and to evaluate the effect of tofersen on pharmacodynamics (PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of clinically manifest ALS.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

158

Fase

  • Fase 3

Uitgebreide toegang

Goedgekeurd te koop aan het publiek. Zie uitgebreid toegangsrecord.

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • New South Wales
      • Macquarie Park, New South Wales, Australië, 2109
        • Macquarie University Hospital
      • Leuven, België, 3000
        • UZ Leuven
      • São Paulo, Brazilië, 04038-002
        • PSEG Centro de Pesquisa Clinica
    • São Paulo
      • São Paulo, São Paulo, Brazilië, 04037-002
        • Hospital Sao Paulo
    • Alberta
      • Calgary, Alberta, Canada, T2N4Z6
        • University of Calgary
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Sunnybrook Health Sciences Centre
    • Quebec
      • Montreal, Quebec, Canada, H4A 3T2
        • Genge Partners
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Duitsland, 89081
        • Universitaetsklinikum Ulm
    • Lower Saxony
      • Hanover, Lower Saxony, Duitsland, 30625
        • Medizinische Hochschule Hannover
    • Paris
      • Paris, Paris, Frankrijk, 75651
        • Groupe Hospitalier Pitie-Salpetriere
      • Torino, Italië, 10124
        • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japan, 890-8520
        • Kagoshima University Hospital
    • Tokyo-To
      • Bunkyō City, Tokyo-To, Japan, 113-8655
        • University of Tokyo Hospital
      • Warsaw, Polen, 01-684
        • Centrum Medyczne NeuroProtect
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polen, 01-684
        • NeuroProtect Sp. z o.o.
      • Valencia, Spanje, 46026
        • Hospital Universitari i Politecnic La Fe
    • South Yorkshire
      • Sheffield, South Yorkshire, Verenigd Koninkrijk, S10 2RX
        • University of Sheffield
    • Arizona
      • Scottsdale, Arizona, Verenigde Staten, 85258
        • HonorHealth Neurology
    • California
      • La Jolla, California, Verenigde Staten, 92093-0949
        • University of California San Diego Medical Center
      • San Francisco, California, Verenigde Staten, 94107
        • California Pacific Medical Center Research Institute
    • Florida
      • Fort Lauderdale, Florida, Verenigde Staten, 33308
        • Holy Cross Hospital
      • Miami, Florida, Verenigde Staten, 33136
        • University of Miami School of Medicine
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30322-4200
        • The Emory Clinic
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60611
        • Northwestern Medicine
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21287
        • Johns Hopkins Hospital
    • Massachusetts
      • Charlestown, Massachusetts, Verenigde Staten, 02129
        • Massachusetts General Hospital, MA
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63110
        • Washington University School of Medicine
    • New York
      • New York, New York, Verenigde Staten, 10032
        • Columbia University Medical center
    • Texas
      • Austin, Texas, Verenigde Staten, 78756
        • Austin Neuromuscular Center
      • Seoul, Zuid -Korea, 04763
        • Hanyang University Seoul Hospital
      • Umeå, Zweden, 90185
        • Norrlands Universitetssjukhus
    • Västerbotten County
      • Umeå, Västerbotten County, Zweden, 90185
        • University Hospital of Umea

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Key Part A Inclusion Criteria:

  • Participants should have a protocol-defined rapidly progressive SOD1 mutation, confirmed by a central reader, or a SOD1 mutation that is approved for inclusion by an external mutation adjudication committee.
  • Participants with plasma NfL level less than the protocol-defined threshold.
  • Participants who are clinically presymptomatic for ALS (i.e., must not have clinically manifest ALS).

Key Part A Exclusion Criteria:

  • History or positive test result at screening for human immunodeficiency virus (HIV). The requirement for testing at Screening may be omitted if it is not permitted by local regulations.

  • Current hepatitis C infection [defined as positive Hepatitis C Virus (HCV) antibody and detectable HCV ribonucleic acid (RNA)]. Participants with positive HCV antibody and undetectable HCV RNA are eligible to participate in the study (United States Centers for Disease Control and Prevention).

  • Current hepatitis B infection (defined as positive for hepatitis B surface antigen (HBsAg) and/or anti-Hepatitis B Core antibody (HBc)). Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive anti-HBc, and positive anti-hepatitis B surface antibody (HBs) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti- HBs) are eligible to participate in the study.

  • History of systemic hypersensitivity reaction to tofersen, the excipients contained in the formulation, and if appropriate, any diagnostic agents to be administered during the study.

  • History of confounding neuromuscular or neurological disorder that is expected to have a progressive (i.e., worsening) course during the study, and/or is expected to be associated with elevations in NF, in the opinion of the Investigator.

  • Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that if not managed optimally could place a participant at an increased risk for intraoperative or postoperative bleeding.

  • Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, suicidal ideation, suicide attempt, or untreated major depression

    ≤ 90 days of screening, which in the opinion of the Investigator would interfere with the study procedures.

  • Treatment with riluzole, edaravone, and/or sodium phenylbutyrate/taurursodiol (also known as ursodoxicoltaurine). If the participant has been on riluzole, edaravone, and/or sodium phenylbutyrate/taurursodiol, the medication(s) must be discontinued for at least 5 half-lives prior to Screening.

  • Use of off-label treatments for ALS.

  • Treatment with another investigational drug (including investigational drugs for ALS through compassionate use programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering RNA, stem cell therapy, or gene therapy is allowed.

  • Anticipated need, in the opinion of the Investigator, for administration of any antiplatelet or anticoagulant medication (e.g., clopidogrel) that cannot be safely continued or held for a Lumbar Puncture (LP) procedure, if necessary, according to local or institutional guidelines and/or Investigator determination.

  • Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment, biological agent, device, or approved therapy for investigational use. Participation in a noninterventional study focused on ALS natural history may be allowed at the discretion of the Investigator.

NOTE: Other protocol defined Inclusion/Exclusion criteria will apply.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Geen tussenkomst: Part A: Natural History Run-in

Participants enrolled in Part A will undergo blood draws approximately once every 28 days to assess NfL levels.

Experimenteel: Part B: Randomized, Double-Blind, Placebo-Controlled

Participants from Part A who meet the protocol-defined NfL threshold and remain presymptomatic may be eligible to participate in Part B. During Part B, participants will receive tofersen 100 milligrams (mg) or placebo via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to approximately 5.6 years.

Administered as specified in the treatment arm

Administered as specified in the treatment arm

Andere namen:
  • BIIB067
  • QALSODY
Experimenteel: Part C: Open-Label Extension

Participants from Part B who develop clinically manifest ALS may be eligible to participate in Part C. During Part C, participants who received placebo in Part B will receive tofersen 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter up to the final maintenance dose visit. Participants who received tofersen during Part B will receive tofersen 100 mg on Days 1, 29, and every 28 days thereafter up to the final maintenance dose visit, with a dose of placebo on Day 15 to maintain the study blind. The combined duration of Part B and Part C is up to approximately 5.6 years.

Administered as specified in the treatment arm

Administered as specified in the treatment arm

Andere namen:
  • BIIB067
  • QALSODY
Experimenteel: Part D: Open-Label Treatment

Participants from Part A who develop clinically manifest ALS prior to randomization in Part B may be eligible to participate in Part D. During Part D, participants will receive tofersen 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.

Administered as specified in the treatment arm

Andere namen:
  • BIIB067
  • QALSODY

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
Part B: Time to Emergence of Clinically Manifest ALS
Tijdsspanne: Up to 5.6 years
Up to 5.6 years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Delen B en C: Percentage deelnemers met de opkomst van klinisch manifeste ALS binnen 24 maanden na de basislijn van deel B
Tijdsspanne: Tot 24 maanden
Tot 24 maanden
Deel B en C: Verandering ten opzichte van de uitgangswaarde in percentage voorspelde langzame vitale capaciteit (SVC)
Tijdsspanne: Tot 5,6 jaar
Tot 5,6 jaar
Deel B en C: Percentage deelnemers met uitkomst in de vorm van sterfgevallen op basis van analyse van de tijd tot overlijden
Tijdsspanne: Tot 5,6 jaar
Tot 5,6 jaar
Deel B, C en D: Aantal deelnemers met bijwerkingen (AE's) en ernstige bijwerkingen (SAE's) tijdens de behandelingsperiode
Tijdsspanne: Deel B en C: maximaal 5,6 jaar en deel D: maximaal 2 jaar
Deel B en C: maximaal 5,6 jaar en deel D: maximaal 2 jaar
Delen B, C en D: Verandering ten opzichte van de uitgangswaarde in plasma NfL-concentraties
Tijdsspanne: Deel B en C: maximaal 5,6 jaar en deel D: maximaal 2 jaar
Deel B en C: maximaal 5,6 jaar en deel D: maximaal 2 jaar
Deel B, C en D: Verandering in de totale SOD1-concentraties van het hersenvocht (CSF)
Tijdsspanne: Deel B en C: maximaal 5,6 jaar en deel D: maximaal 2 jaar
Deel B en C: maximaal 5,6 jaar en deel D: maximaal 2 jaar
Parts B and C: Change in ALS Functional Rating Scale (ALSFRS-R) Total Score
Tijdsspanne: Up to 5.6 years

The ALSFRS-R measures 4 functional domains: respiratory, bulbar function, gross motor skills, and fine motor skills. There are 12 questions, each scored from 0 to 4, for a total possible score of 48, with higher scores representing better function.

Up to 5.6 years
Parts B and C: Percentage of Participants with Outcome as Death or Permanent Ventilation Based on Time to Death or Permanent Ventilation Analysis
Tijdsspanne: Up to 5.6 years

Permanent ventilation is defined as ≥22 hours of invasive or non-invasive mechanical ventilation per day for ≥21 consecutive days.

Up to 5.6 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: Medical Director, Biogen

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

17 mei 2021

Primaire voltooiing (Geschat)

7 augustus 2027

Studie voltooiing (Geschat)

25 mei 2028

Studieregistratiedata

Eerst ingediend

20 april 2021

Eerst ingediend dat voldeed aan de QC-criteria

20 april 2021

Eerst geplaatst (Werkelijk)

23 april 2021

Updates van studierecords

Laatste update geplaatst (Werkelijk)

4 november 2026

Laatste update ingediend die voldeed aan QC-criteria

3 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 233AS303
  • 2023 (Subsidie/contract van de Amerikaanse NIH)
  • 2023-505641-12 (Andere identificatie: EU Trial (CTIS) Number)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren